Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–16 of 16 results
Advanced filters: Author: Roy Fleischmann Clear advanced filters

  • Identifying jets originating from heavy quarks plays a fundamental role in hadronic collider experiments. In this work, the ATLAS Collaboration describes and tests a transformer-based neural network architecture for jet flavour tagging based on low-level input and physics-inspired constraints.

    • G. Aad
    • E. Aakvaag
    • L. Zwalinski
    ResearchOpen Access
    Nature Communications
    Volume: 17, P: 1-22

  • The positive results of the phase II programme of fostamatinib, developed to target the spleen tyrosine kinase pathway in rheumatoid arthritis (RA), have not been replicated in phase III. What implications might the results have for the development of other oral inhibitors of intracellular kinases in the treatment of RA?

    • Roy M. Fleischmann
    News & Views
    Nature Reviews Rheumatology
    Volume: 11, P: 4-6

  • Entanglement was observed in top–antitop quark events by the ATLAS experiment produced at the Large Hadron Collider at CERN using a proton–proton collision dataset with a centre-of-mass energy of √s  = 13 TeV and an integrated luminosity of 140 fb−1.

    • G. Aad
    • B. Abbott
    • L. Zwalinski
    ResearchOpen Access
    Nature
    Volume: 633, P: 542-547

  • Physician–investigators carrying out clinical research have moral, ethical and legal responsibilities. A variety of official documentation must be in place before a trial commences, and good clinical practice must be followed throughout. A suitable infrastructure, in terms of equipment, staff and space, is also required. These issues are outlined in this article.

    • Roy Fleischmann
    Reviews
    Nature Clinical Practice Rheumatology
    Volume: 3, P: 234-239

  • A suitable infrastructure and adherence to regulatory requirements are required to establish a successful clinical trial unit. Once in place, studies must be acquired, contracts negotiated and patients recruited before the clinical investigation can begin. These aspects, which, if successfully carried out, will improve the chances of obtaining future studies, are discussed in this article.

    • Roy Fleischmann
    Reviews
    Nature Clinical Practice Rheumatology
    Volume: 3, P: 459-463

  • The ATLAS Collaboration reports the observation of the electroweak production of two jets and a Z-boson pair. This process is related to vector-boson scattering and allows the nature of electroweak symmetry breaking to be probed.

    • G. Aad
    • B. Abbott
    • L. Zwalinski
    ResearchOpen Access
    Nature Physics
    Volume: 19, P: 237-253

  • Biosimilar therapeutics for immune-mediated disease are approved in many countries and are increasingly being utilized in clinical practice. Although much has been written about the effectiveness and safety of biosimilars, less focus has been placed on why, how and when (or when not) to use these medications — until now.

    • Roy Fleischmann
    News & Views
    Nature Reviews Rheumatology
    Volume: 13, P: 701-703

  • Tyrosine kinase 2 (TYK2), a Janus kinase family member, is involved in immune signalling and is implicated in autoimmune diseases such as systemic lupus erythematosus; inhibitors of TYK2 show promise in treating various diseases and potentially offer advantages over other Janus kinase inhibitors.

    • Eric Morand
    • Joseph F. Merola
    • Roy Fleischmann
    Reviews
    Nature Reviews Rheumatology
    Volume: 20, P: 232-240